Article: Provectus Pharma gets $20.75M financing from Cornell Capital.(Provectus Pharmaceuticals Inc., Cornell Capital Partners L.P.)(Brief Article)

Provectus Pharmaceuticals of the USA says that it has received a $20.75 million financial commitment from Cornell Capital Partners.

Under the terms of the funding agreements with Cornell Capital, Provectus has obtained $750,000 in convertible securities and a firm commitment of $20 million under a standby equity distribution agreement. Provectus may, at its discretion, issue shares to Cornell at any time over the next two years, with the maximum aggregate amount of the equity placements being $20 million. Subject to this limitation, Provectus may draw down ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!